Skip to content

Vaxcyte, Inc. PCVX Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

Pfizer logo
PfizerPFE
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s accrued manufacturing costs?
Vaxcyte, Inc. (PCVX) reported accrued manufacturing costs of $7.99M in Q1 2026.
How has Vaxcyte, Inc.'s accrued manufacturing costs changed year-over-year?
Vaxcyte, Inc.'s accrued manufacturing costs increased by 33.3% year-over-year, from $5.99M to $7.99M.
What is the long-term trend for Vaxcyte, Inc.'s accrued manufacturing costs?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s accrued manufacturing costs has grown at a 140.8% compound annual growth rate (CAGR), from $284K to $23M.